Arcus is an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs.
Arcus was incorporated in Delaware on April 30, 2015.
Arcus’s corporate headquarters are located at: 3928 Point Eden Way Hayward, CA 94545
Arcus’s fiscal year end is December 31st.
Ernst & Young is Arcus’s independent registered public accounting firm.
Arcus shares trade under the ticker symbol “RCUS” on the New York Stock Exchange. Arcus’s initial public offering was on March 14, 2018.
Shares can be purchased through a licensed securities broker. Arcus does not have a direct share purchase program.
Arcus does not pay cash dividends on its shares.
The CUSIP number is 03969F 109.
Arcus's transfer agent is Computershare.
Computershare Trust Company, N.A. 150 Royall Street Canton, Massachusetts 02021 (800) 962-4284.
Please see the SEC Filings section of our website.
Please submit an inquiry via our contact form.